NCT05122559Active, not recruitingPhase 2
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
Randomized Controlled Trial of N-acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 11 Mar 2026
Brief summary (registry, in English)
This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 98 (estimated)
- First submitted
- 8 Nov 2021
- Start date
- 16 Feb 2022
- Primary completion date
- Feb 2027
- Lead sponsor
- Emmanuelle Waubant, MD PhD
- Diseases
- Multiple sclerosis
- NCT number
- NCT05122559
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 98
- From 16 Feb 2022 to the primary completion date, Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- MS relapses in the previous 6 months
- oral glucocorticosteroid treatment within the prior 3 months
- planned surgery or move within 15 months
- use of medications/supplements with antioxidant properties (including over-the-counter NAC)
Other illness
- history of bleeding disorders
- current treatment for active malignancy or metastatic malignancy treated in the past year
- alcohol or substance use disorder
- allergy to NAC
Lab values
- abnormal liver function testing (aminotransferase (AST) or alanine aminotransferase (ALT) \>2 times upper limit of normal)
Other
- patient with issues undergoing MRI scans
- pregnancy or breastfeeding
- women of child-bearing potential not able to utilize an effective form of contraception for the duration of the study
- active gastrointestinal ulcers
Who the study is looking for
- \- 40-70 (inclusive) years in age,
- meet 2017 McDonald criteria (Thompson 2018),
- patients with primary or secondary progressive MS (Thompson 2018),
- at least 2 years since progressive symptom onset,
- evidence of clinical changes over the previous 2 years unrelated to relapses: increased EDSS or 20% slowing on 25-foot walk, change of ambulatory support, cognitive change documented on cognitive testing. Progression defined by patients in terms of ambulation perimeter or type of support to ambulate are acceptable if aforementioned physician-based measure changes are not available.
- EDSS score 3.0 to 7.0 (inclusive),
- can be on a stable disease-modifying treatment initiated \> 3 months prior to screening,
- can be on stable doses of dalfampridine initiated at least one month before screening.
Age in the registry: 40 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.